Screener
Alkermes ALKS LYBALVI — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alkermes’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 9:22 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-319022
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| VIVITROL | $124,454 | $121,660 | $236,888 | $222,656 |
| ARISTADA and ARISTADA INITIO | 96,719 | 101,295 | 190,543 | 174,770 |
| LYBALVI | 93,979 | 84,280 | 186,343 | 154,302 |
| LUMRYZ | 96,572 | — | 136,064 | — |
| Total product sales, net | $411,724 | $307,235 | $749,838 | $551,728 |
Item 1. Condensed Consolidated Financial Statements:
FAQ
- What is Alkermes's LYBALVI — revenue?
- Alkermes (ALKS) reported LYBALVI — revenue of $93.98M in Q2 2026.
- How has Alkermes's LYBALVI — revenue changed year-over-year?
- Alkermes's LYBALVI — revenue increased by 11.5% year-over-year, from $84.28M to $93.98M.
- What is the long-term trend for Alkermes's LYBALVI — revenue?
- Over 4 years (2021 to 2025), Alkermes's LYBALVI — revenue has grown at a 154.9% compound annual growth rate (CAGR), from $8.22M to $346.69M.
- What does LYBALVI — revenue mean?
- This metric represents the total net revenue generated from the sale of a specific pharmaceutical product, excluding any taxes collected from customers. It reflects the commercial success and market adoption of the therapeutic asset within the company's portfolio. This figure is a primary indicator of the product's lifecycle stage and its contribution to the company's overall top-line growth.
Ask your AI about Alkermes's lybalvi — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude